Hosted in collaboration with Canary Wharf Group and Kadans, this event brings together experts and innovators shaping the future of gene therapy. Engage with peers on a discussion about accelerating the journey from transformative science to real-world adoption and maximising the patient impact of these potentially curative treatments.

Programme
15.00 – Registration and Networking
15.30 – Welcome from One Nucleus and Canary Wharf/Kadans
15.40 – Keynote – Setting the scene for the potential of gene-based therapeutics
Realising potential of genomic medicines: how to make it happen, Daria Marsh, Head of Bioprocess, Technology and Process Innovation, CGT Catapult
16.05 – Gene therapies in tackling disease 
Dr Ellen Knuepfer, Lecturer in Vaccinology, Royal Veterinary College 
Prof Richard Piercy, Professor of Comparative Neuromuscular Disease, Royal Veterinary College
16.45 – Tea/Coffee Break
17.20 – Regulatory and ethical considerations 
Regulatory hurdles, Katie Binley, CSO, Ikarovec
A patient perspective, Ron Jortner, Founder, Aspire Biosciences & Mel Dixon, Cure DHDDS
17.50 – Panel discussion on ‘Commercial adoption of genomic based therapies’
Moderator: Eddie Blair, Board Member, Quadrum Institute
Panellists: 
Dr Ellen Knuepfer, Lecturer in Vaccinology, Royal Veterinary College 
Prof Richard Piercy, Professor of Comparative Neuromuscular Disease, Royal Veterinary College
Katie Binley, CSO, Ikarovec 
Gareth Williams, Partner, Marks & Clerk
18.25 – Closing remarks followed by networking drinks
19.30 – Close

Event Supporters

Registration: This event is free to attend and open to all. 

Sponsorship: Please contact alicia@onenucleus.com if you are interested in discussing sponsorship opportunities.

Please note we will be securely sharing your email address for the purposes of building security with the host only. QR codes will be sent to email addresses only to allow for access past the ground floor turnstiles up to Level 39.